Table 2.
Thrombin generation parameters with the different combined oral contraceptive associations at baseline and cycle 6
| ETP (nM.min) | Peak height (nM) | Lag time (min) | Time to peak (min) | mVRI (nM/min) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Cycle 6 | Relative diff. (%) | P value | Baseline | Cycle 6 | Relative diff. (%) | P value | Baseline | Cycle 6 | Relative diff. (%) | P value | Baseline | Cycle 6 | Relative diff. (%) | P value | Baseline | Cycle 6 | Relative diff. (%) | P value | |
| EE/LNG | 1219 ± 180 |
1588 ± 204 |
32.0 ± 20.5 |
<0.0001 | 192.5 ± 39.6 |
287.3 ± 43.7 |
53.6 ±29.4 |
<0.0001 | 3.01 ± 0.51 |
2.65(5) ± 0.40 |
−10.5 ± 12.9(5) |
0.0005 | 6.72 ± 1.28 |
5.47 ± 0.91 |
−18.0 ± 8.5 |
<0.0001 | 55.6 ± 19.0 |
107.1 ± 29.6 |
105.0 ± 56.4 |
<0.0001 |
| EE/DRSP | 1226 ± 146 |
1613 ± 197 |
32.8
± 19.0 |
<0.0001 | 189.7 ± 33.8 |
304.3 ± 35.6 |
65.5 ± 38.4 |
<0.0001 | 2.97 ± 0.43 |
2.49 ± 0.29 |
−15.2(5) ± 10.4 |
<0.0001 | 6.72 ± 0.91 |
5.13 ± 0.58 |
−23.0 ± 8.1 |
<0.0001 | 52.8 ± 15.8 |
118.5 ± 24.9 |
143.6 ± 98.8 |
<0.0001 |
| E4/DRSP | 1257 ±150 |
1456 ± 186 |
16.8 ± 15.9 |
<0.0001 | 218.5 ± 39.0 |
253.2 ± 42.6 |
17.3 ± 16.5 |
<0.0001 | 2.83 ± 0.39 |
2.72 ± 0.32 |
−2.4(5) ± 15.8 |
0.1632 | 6.02 ± 0.80 |
5.79 ± 0.78 |
−3.2 ± 12.2 |
0.0747 | 72.2 ± 23.0 |
87.2 ± 28.5 |
24.3 ±27.9 |
<0.0001 |
| P-valuea | 0.6167 | 0.0042 | 0.0010 | / | 0.0054 | <0.0001 | <0.0001 | / | 0.2636 | 0.0275 | 0.0013 | / | 0.0078 | 0.0046 | <0.0001 | 0.0004 | 0.0001 | <0.0001 | / | |
Abbreviations: DRSP, drospirenone; E4, estetrol; EE, ethinylestradiol; ETP, endogenous thrombin potential; LNG, levonorgestrel; mVRI, mean velocity rate index.
a
P value had been estimated by using an ordinary 1-way ANOVA. A Tukey multiple comparisons test, with a single pooled variance, has been run to assess the difference between the groups. P values < 0.05 are considered statistically significant and appear in bold.